Michelle A Kendall1, Umesh Lalloo2, Courtney V Fletcher3, Xingye Wu1, Anthony T Podany3, Sandra W Cardoso4, Prudence Ive5, Constance A Benson6. 1. Center for Biostatistics in AIDS Research, Harvard T.H. Chan School of Public Health, Boston, Massachusetts, USA. 2. Enhancing Care Foundation, Durban International Clinical Research Site (CRS), Durban, South Africa. 3. UNMC Center for Drug Discovery, University of Nebraska Medical Center, Omaha, Nebraska, USA. 4. Instituto de Pesquisa Clinica Evandro Chagas (IPEC) CRS, Rio de Janeiro, Brazil. 5. Clinical HIV Research Unit, Department of Internal Medicine, School of Clinical Medicine, Faculty of Health Sciences, University of the Witwatersrand, Johannesburg, South Africa. 6. Antiviral Research Center, University of California, San Diego, San Diego, California, USA.
Abstract
BACKGROUND: Protease inhibitor-based antiretroviral therapy may be used in resource-limited settings in persons with human immunodeficiency virus and tuberculosis (HIV-TB). Data on safety, pharmacokinetics/pharmacodynamics (PK/PD), and HIV-TB outcomes for lopinavir/ritonavir (LPV/r) used with rifampin (RIF) or rifabutin (RBT) are limited. METHODS: We randomized adults with HIV-TB from July 2013 to February 2016 to arm A, LPV/r 400 mg/100 mg twice daily + RBT 150 mg/day; arm B, LPV/r 800 mg/200 mg twice daily + RIF 600 mg/day; or arm C, LPV/r 400 mg/100 mg twice daily + raltegravir (RAL) 400 mg twice daily + RBT 150 mg/day. All received two nucleoside reverse transcriptase inhibitors and other TB drugs. PK visits occurred on day 12 ± 2. Within-arm HIV-TB outcomes were summarized using proportions and 95% CIs; PK were compared using Wilcoxon tests. RESULTS: Among 71 participants, 52% were women; 72% Black; 46% Hispanic; median age, 37 years; median CD4+ count, 130 cells/mm3; median HIV-1 RNA, 4.6 log10 copies/mL; 46% had confirmed TB. LPV concentrations were similar across arms. Pooled LPV AUC12 (157 203 hours × ng/mL) and Ctrough (9876 ng/mL) were similar to historical controls; RBT AUC24 (7374 hours × ng/mL) and Ctrough (208 ng/mL) were higher, although 3 participants in arm C had RBT Cmax <250 ng/mL. Proportions with week 48 HIV-1 RNA <400 copies/mL were 58%, 67%, and 61%, respectively, in arms A, B, and C. CONCLUSIONS: Double-dose LPV/r+RIF and LPV/r+RBT 150mg/day had acceptable safety, PK and TB outcomes; HIV suppression was suboptimal but unrelated to PK. Faster RBT clearance and low Cmax in 3 participants on RBT+RAL requires further study.
BACKGROUND: Protease inhibitor-based antiretroviral therapy may be used in resource-limited settings in persons with human immunodeficiency virus and tuberculosis (HIV-TB). Data on safety, pharmacokinetics/pharmacodynamics (PK/PD), and HIV-TB outcomes for lopinavir/ritonavir (LPV/r) used with rifampin (RIF) or rifabutin (RBT) are limited. METHODS: We randomized adults with HIV-TB from July 2013 to February 2016 to arm A, LPV/r 400 mg/100 mg twice daily + RBT 150 mg/day; arm B, LPV/r 800 mg/200 mg twice daily + RIF 600 mg/day; or arm C, LPV/r 400 mg/100 mg twice daily + raltegravir (RAL) 400 mg twice daily + RBT 150 mg/day. All received two nucleoside reverse transcriptase inhibitors and other TB drugs. PK visits occurred on day 12 ± 2. Within-arm HIV-TB outcomes were summarized using proportions and 95% CIs; PK were compared using Wilcoxon tests. RESULTS: Among 71 participants, 52% were women; 72% Black; 46% Hispanic; median age, 37 years; median CD4+ count, 130 cells/mm3; median HIV-1 RNA, 4.6 log10 copies/mL; 46% had confirmed TB. LPV concentrations were similar across arms. Pooled LPV AUC12 (157 203 hours × ng/mL) and Ctrough (9876 ng/mL) were similar to historical controls; RBT AUC24 (7374 hours × ng/mL) and Ctrough (208 ng/mL) were higher, although 3 participants in arm C had RBT Cmax <250 ng/mL. Proportions with week 48 HIV-1 RNA <400 copies/mL were 58%, 67%, and 61%, respectively, in arms A, B, and C. CONCLUSIONS: Double-dose LPV/r+RIF and LPV/r+RBT 150mg/day had acceptable safety, PK and TB outcomes; HIV suppression was suboptimal but unrelated to PK. Faster RBT clearance and low Cmax in 3 participants on RBT+RAL requires further study.
Authors: G Ramachandran; P K Bhavani; A K Hemanth Kumar; R Srinivasan; K Raja; V Sudha; S Venkatesh; C Chandrasekaran; S Swaminathan Journal: Int J Tuberc Lung Dis Date: 2013-12 Impact factor: 2.373
Authors: Eric H Decloedt; Helen McIlleron; Peter Smith; Concepta Merry; Catherine Orrell; Gary Maartens Journal: Antimicrob Agents Chemother Date: 2011-05-02 Impact factor: 5.191
Authors: Vanitha Sekar; Ludo Lavreys; Tom Van de Casteele; Cindy Berckmans; Sabrina Spinosa-Guzman; Tony Vangeneugden; Martine De Pauw; Richard Hoetelmans Journal: Antimicrob Agents Chemother Date: 2010-07-26 Impact factor: 5.191
Authors: William Burman; Debra Benator; Andrew Vernon; Awal Khan; Brenda Jones; Claudia Silva; Chris Lahart; Stephen Weis; Barbara King; Bonita Mangura; Marc Weiner; Wafaa El-Sadr Journal: Am J Respir Crit Care Med Date: 2005-08-18 Impact factor: 21.405
Authors: Lee C Winchester; Anthony T Podany; Joshua S Baldwin; Brian L Robbins; Courtney V Fletcher Journal: J Pharm Biomed Anal Date: 2014-11-18 Impact factor: 3.935
Authors: Shetty Ravi Dyavar; Timothy M Mykris; Lee C Winchester; Kimberly K Scarsi; Courtney V Fletcher; Anthony T Podany Journal: Sci Rep Date: 2020-07-28 Impact factor: 4.379